JPRN-UMIN000032570已完成未知
Evaluation of everolimus pneumonitis and clinical efficacy: a multi-institutional retrospective study - Evaluation of everolimus pneumonitis and clinical efficacy
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie-steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis:-Cardiac index = 2,1 l/min/m2-6 MWD = 380 m-systolic RR = 120 mmHg-VO2max = 11 l/min/kg-SVO2 = 60%-Hf = 90/min-probabilty of survival for one year = 0,7 following the NIH-formularMedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-004224-37-DEniversität Leipzig10
招募中
Unknown
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
已完成
不适用
Assessment of efficy and safety of everolimus in Japanese patients with mRCCrenal cell carcinomaJPRN-UMIN000009620Tokyo Afinitor Clinical Trial Group200
已完成
4 期
prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicitymamma carcinoma10006291breast cancerNL-OMON38563niversitair Medisch Centrum Sint Radboud100
进行中（未招募）
1 期
prediction of lung problems as a side effect of treatment with everolimus for patients with breast cancerMedDRA version: 20.0 Level: LLT Classification code 10072737 Term: Advanced breast cancer System Organ Class: 100000004864breast cancerEUCTR2013-002258-60-NLRadboud University Nijmegen Medical Centre100